JEMPERLI
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEMPERLI (dostarlimab) is a PD-1 blocking monoclonal antibody approved in April 2021 for treating cancers with specific molecular profiles. It works by unleashing the immune system to recognize and attack tumor cells by blocking the programmed death receptor-1 pathway. The drug is currently in peak commercial lifecycle, indicating strong market establishment.
$0.002BPart D
PeakPeak lifecycle positioning indicates mature market presence with established sales infrastructure; commercial teams are optimizing market penetration rather than building from launch.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JEMPERLI roles are heavily skewed toward commercial functions, particularly regional sales leadership and market access strategy, reflecting a mature product in peak lifecycle requiring revenue optimization and payer management. Career progression opportunities favor sales executives and access strategists who can navigate a competitive immunotherapy landscape and manage narrowing margins.
Regional Sales Director
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.